Brief: Galapagos Presented New Atalanta-1 Cell Therapy Data In MCL

Lakefront Biotherapeutics NV

08/12/2025 06:34

Dec 8 (Reuters) - Galapagos NV GLPG.AS:

REG-GALAPAGOS PRESENTED NEW ATALANTA-1 CELL THERAPY DATA IN MCL AT ASH 2025

AMONG INFUSED PATIENTS OBJECTIVE RESPONSE RATE (ORR) WAS 100%, WITH COMPLETE RESPONSE RATE (CRR) OF 96%

GLPG5101 SHOWS ENCOURAGING SAFETY PROFILE IN MCL STUDY

GALAPAGOS REMAINS FOCUSED ON THE INTENTION TO WIND DOWN THE CELL THERAPY ACTIVITIES

GLPG5101 DEMONSTRATED ROBUST IN VIVO CAR T-CELL EXPANSION AND LONG-TERM PERSISTENCE

Source text: ID:nGNE4SXT97

Further company coverage: GLPG.AS

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))